In Brief: Oncor
This article was originally published in The Gray Sheet
Executive SummaryOncor: Receives a $750,000 Phase II SBIR (Small Business Innovation Research) grant from NIH. The grant will go towards Oncor's analysis of human telomeres -- a cap at the end of human chromosomes essential for the maintenance of their structure and stability. Oncor plans to develop a panel of chromosome-specific telomere gene probes that the company anticipates will be helpful in "elucidating the role of telomeres in cancer and other genetic disorders"...
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.